Showing results (541-550 of 661) with videos related to
Sort By:
Pageof 67
Acta Oncologica (Stockholm, Sweden)|February 15, 2021
Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection marginsRebecca K Bott, Kerri Beckmann, Janine Zylstra, et al.British Journal of Haematology|May 22, 2020
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trialMary Gleeson, Nicholas Counsell, David Cunningham, et al.Trials|August 31, 2017
A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trialNick J Battersby, Mit Dattani, Sheela Rao, et al.British Journal of Haematology|August 2, 2016
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trialMary Gleeson, Eliza A Hawkes, David Cunningham, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2018
Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL)Qian Shi, Norbert Schmitz, Fang-Shu Ou, et al.The Journal of Molecular Diagnostics : JMD|March 10, 2015
Technical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissuesShenli Zhang, Iain B Tan, Nur S Sapari, et al.The Lancet. Oncology|September 22, 2014
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialHansjochen Wilke, Kei Muro, Eric Van Cutsem, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2012
Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort StudyAnthony J Swerdlow, Rosie Cooke, Andrew Bates, et al.European Journal of Cancer (Oxford, England : 1990)|December 4, 2014
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapyPaul Ruff, David R Ferry, Radek Lakomỳ, et al.Journal for Immunotherapy of Cancer|December 11, 2021
Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survivalManish A Shah, David Cunningham, Jean-Philippe Metges, et al.Pageof 67